drugset / Trial / NCT00837174
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat) non-Hodgkin Lymphoma, and to determine the safety and tolerability of this regimen.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-05
- Completion
- 2012-05
Outcome
Outcome not reported
Stopped (Business): “Study never activated/opened as funding source and other support not available.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |